Clinical applications of therapeutic hemapheresis

Journal of Intensive Care Medicine

Volumn 11, Issue 3, 1996, Pages 149-161

  Rososhansky, Sarah ^a   Szymanski, Irma O ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSEL INJURY; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HUMAN; HYPOTENSION; LEUKOCYTOSIS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; TECHNIQUE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA; VASCULAR ACCESS;

EID: 0029879869     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1177/088506669601100302     Document Type: Review

References (115)

1. Solomon A, Fahey JL. Plasmapheresis therapy in macroglobulinemia. Ann Intern Med 1963;58:789-800
2. Ciavarella D. Blood processors and cell separators. Transfusion Sci 1989;10:165-184
3. Taft EG. Therapeutic apheresis. Hum Pathol 1983;14: 235-240
4. AMA Panel on Therapeutic Plasmapheresis. Current status of therapeutic plasmapheresis and related techniques. JAMA 1985;253:819-825
5. Clinical Applications Committee, American Society for Apheresis. Clinical applications of therapeutic apheresis. J Clin Apheresis 1986;3:1-92
6. Strauss RG, Ciavarella D, Gilcher RO, et al. Clinical applications of therapeutic hemapheresis. J Clin Apheresis 1993;8:190-194
7. Grishaber JE, Cunningham MC, Rohret PA, Strauss RG. Analysis of venous access for therapeutic plasma exchange in patients with neurological disease. J Clin Apheresis 1992;7:119-123.
8. Thompson L. Central venous catheters for apheresis access. J Clin Apheresis 1992;7:154-157
9. Hirano T, Yoshioka H. Superiority of internal jugular venipuncture to subclavian venipuncture as a central venous catheterization. Vasc Surg 1994;28:337-340
10. Fosburg M, Dolan M, Propper R, et al. Intensive plasma exchange in small and critically ill pediatric patients: techniques and clinical outcome. J Clin Apheresis 1983; 1:215-224
11. Halligan GE. Feasibility and safety of therapeutic apheresis in a pediatric population. J Clin Apheresis 1984;2:149-150
12. Gurland HJ. Therapeutic apheresis update. Adv Exp Med Biol 1989;260:193-201
13. Alving BM, Hojima Y, Pisano JJ, et al. Hypotension associated with prekallikrein activator (Hageman-factor fragments.) in plasma protein fraction. N Engl J Med 1978; 299:66-70
14. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297: 1386-1389
15. Shepard KV, Bukowski RM. The treatment of thrombotic trombocytopenic purpura with exchange transfusions, plasma infusions and plasma exchange. Semin Hematol 1987;24:178-193
16. Roberts AW, Gillett FA, Fleming SJ. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange. J Clin Apheresis 1991;6:150-154
17. Task Force of the College of American Pathologists. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 1994;271:777-781
18. Orlin JB, Berkman EM. Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. Blood 1980;56:1055-1059
19. Snyder HW Jr, Cochran SK, Balint JP Jr, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79:2237-2245
20. ® Column) immunoadsorption. Semin Hematol 1989;26(suppl):15-18
21. ® columns. Semin Hematol 1989;26(suppl):31-41
22. Gjörstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfusion Sci 1990;11:281-302
23. Palmer A, Welsh K, Gjörstrup P, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989;1:10-12
24. Ross CN, Gaskin G, Gregor-Macgregor S, et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993;55:785-789
25. Boughton BJ, Payne A, Serman A, Owen C. Elective surgery in a haemophilic patient with high titre inhibitors: use of extracorporeal protein A immunoabsorption. J Clin Pathol 1990;43:172
26. Uehlinger J, Button GR, McCarthy J, et al. Immunoadsorption for coagulation factor inhibitors. Transfusion 1991;31: 265-269
27. Watt RM, Bunitsky K, Faulkner EB, et al. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Transfusion Sci 1992;13:233-253
28. Rosenow F, Haupt WF, Grieb P, et al. Plasma exchange and selective adsorption in Guillain-Barré Syndrome - a comparison of therapies by clinical course and side effects. Transfusion Sci 1993;14:13-15
29. Avanzi G, Marconi G. Semiselective immunoadsorption of anti-AChR abs on tryptophan column in myasthenia gravis. Clinical experience in 32 patients. Transfusion Sci 1993; 14:17-21
30. Yamamoto A, Kokima SH, Shiba-Harada M, et al. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 1992;16:177-181
31. Mimori A, Takahashi K, Mitamura T, et al. Clinical evaluation of three types of plasmapheresis in a patient with type IIa familial hypercholesterolemia. J Clin Apheresis 1987;3:209-215
32. Richter WO, Jacob BG, Ritter MM, et al. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993;42:888-894
33. Kasprisin DO, McLeod BC. Questions and answers. J Clin Apheresis 1992;7:218
34. Pearlman ES, Litty CA, Edger N, Ballas SK. Effect of therapeutic plasmapheresis on coagulation parameters. J Clin Apheresis 1994;9:202-203
35. Hartung HP, Reiners K, Schmidt B, et al. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53
36. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-268
37. Schlansky R, DeHoratius RJ, Pincus T, Tung KSK. Plasmapheresis in systemic lupus erythematosus. Arthritis Rheum 1981;24:49-53
38. Hughes RAC. Plasma exchange in Guillain-Barré syndrome and related disorders. Transfusion Sci 1993;14:3-8
39. Amblard P, Reymond J-L, Beani J-C, et al. Pemphigoide bulleuse. Efficacité et limite thérapeutique des plasmaphéréses. Nouv Presse Med 1980;9:1446
40. Silva VA, Seder RH, Weintraub LR. Synchronization of plasma exchange and cyclophosphamide in severe and refractory autoimmune hemolytic anemia. J Clin Apheresis 1994;9:120-123
41. Jones JV. Plasmapheresis in SLE. Clin Rheum Dis 1982; 8:243-260
42. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991; 18:270-276
43. Lupus Plasmapheresis Study Group. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. J Clin Apheresis 1991;6:40-47
44. Roujeau J-C. Plasmapheresis therapy of pemphigus and bullous pemphigoid. Semin Dermatol 1988;7:195-200
45. Silberstein LE, Berkman EM. Plasma exchange in autoimmune hemolytic anemia (AIHA). J Clin Apheresis 1983;1: 238-242
46. Sutton DMC, Nair RC, Rock G, The Canadian Apheresis Study Group. Complications of plasma exchange. Transfusion 1989;29:124-127
47. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis 1994;9:1-5
48. Huestis DW. Adverse effects in donors and patients subjected to hemapheresis. J Clin Apheresis 1984;2:81-90
49. Rock GA, Herbert CA, Members of the Canadian Apheresis Study Group. Therapeutic apheresis in Canada. J Clin Apheresis 1992;7:47-48
50. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-761
51. Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992;32:589-592
52. Sutton DMC, Cardella CJ, Uldall PR, Deveber GA. Complications of intensive plasma exchange. Plasma Ther 1981; 2:19-23
53. Hester JP, Wallerstein RO. Peripheral blood stem cell transplantation for breast cancer patients with bone marrow metastases using GM-CSF priming. Transfusion Sci 1993; 14:65-69
54. Hillyer CD, Tiegerman KO, Berkman KM. Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator. Transfusion 1991;31:327-332
55. James P. Collection of peripheral blood stem cells on spectra. J Clin Apheresis 1994;9:33-34
56. Sultan Y, Bussel A, Maisonneuve P, et al. Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease. Transfusion 1979;19: 588-593
57. Kornfeld P, Fox S, Maier K, Mahjoub M. Ten years experience with therapeutic apheresis in a community hospital. J Clin Apheresis 1992;7:63-68
58. Evans RT, MacDonald R, Robinson A. Suxamethonium apnoea associated with plasmaphoresis. Anesthesia 1980; 35:198-201
59. Huestis DW. Risks and adverse reactions associated with hemapheresis. In: MacPherson JL, Kasparin DO, eds. Therapeutic hemapheresis, vol I. Boca Raton, FL: CRC Press, 1985:39-46
60. Friedberg RC, Fischer JS, McClellan SO. Plasmapheresis-mediated clearance of vancomycin, gentamicin, and digoxin. Transfusion 1994;34(suppl):3S
61. Tielemans C, Madhoun P, Lenaers M, et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38:982-984
62. Keller C, Grützmacher P, Bahr F, et al. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet 1993;341:60-61
63. Siami G, Morrow J, James L, Stone W. Anaphylactoid reactions associated with EVAL hollow fiber plasma filter pheresis and ACE-inhibitors. J Clin Apheresis 1993;8:52
64. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994;34:891-894
65. Brecher ME, Owen HG, Collins ML. Apheresis and ACE inhibitors. Transfusion 1993;33:963-964
66. Bertram JH, Snyder HW Jr, Gill PS, et al. Protein A immunoadsorption therapy in HIV related immune thrombocytopenia: a preliminary report. Artif Organs 1988;12:484-490
67. Smith RE, Gottschall JL, Pisciotta AV. Life-threatening reaction to staphylococcal protein A immunomodulation. J Clin Apheresis 1992;7:4-5
68. Nand S, Bayer R, Hubbell E, Messmore H. Thromboembolic complications during protein A immunoadsorption therapy. Blood 1990;76:388a
69. Morrison FS, Huestis DW. Toxicity of the staphylococcal protein A imunoadsorption column. J Clin Apheresis 1992;7:171-172
70. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1994;331:792-800
71. Quillen K, Magarace L, Flanagan J, Berkman FM. Vascular erosion caused by a double-lumen central venous catheter during therapeutic plasma exchange. Transfusion 1995; 35:510-512
72. Grishaber JE, Cunningham MC, Rohret PA, Strauss RG. Analysis of venous access for therapeutic plasma exchange in patients with neurological disease. J Clin Apheresis 1992;7:119-123
73. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982;60:279-283
74. Radovic M, Balint B, Milenkovic L, et al. Therapeutic leukapheresis. Transfusion Sci 1991;12:193-196
75. McLeod BC, Strauss RG, Ciavarella D, et al. Management of hematological disorders and cancer. J Clin Apheresis 1993;8:211-230
76. Hemapheresis. In: Walker RH, ed. AABB technical manual, ed 11. Bethesda, MD: American Association of Blood Banks, 1993:29-49
77. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446
78. Dwosh IL, Giles AR, Ford PM, et al. Plasmapheresis therapy in rheumatoid arthritis. N Engl J Med 1983;308:1124-1129
79. Lewis EJ, Hunsicker LG, Lan S-K et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373-1379
80. Kasprisin DO, Strauss RG, Ciavarella D, et al. Management of metabolic and miscellaneous disorders. J Clin Apheresis 1993;8:231-241
81. Weinstein R, Sato PTS, Shelton K, et al. Successful management of paraprotein-associated peripheral polyneuropathies by immunoadsorption of plasma with staphylococcal protein A. J Clin Apheresis 1993;8:72-77
82. McKhann GM. Guillain-Barré syndrome: clinical and therapeutic observations. Ann Neurol 1990;27(suppl):S13-S16
83. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35: 1096-1104
84. van der Meché FGA, Schmitz PIM, The Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129
85. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036
86. Littlewood R, Bajada S. Successful plasmapheresis in the Miller-Fisher syndrome. Br Med J 1981;282:778
87. Seybold MF. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1987;505:584-587
88. Lisak RP. Plasma exchange in neurologic diseases. Arch Neurol 1984;41:654-657
89. Kwaan HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:71-81
90. Dolislager D, Tune B. The hemolytic-uremic syndrome. Spectrum of severity and significance of prodrome. Am J Dis Child 1978;132:55-58
91. Gutterman LA. Thrombotic thrombocytopenic purpura: prospective treatment with a standardized regimen. Transfusion Sci 1992;13:45-51
92. Rossi EC, Green D, Del Greco F. The use of inhibitors of platelet function in thrombotic microangiopathy. In: Remuzzi G, Mecca G, De Gaetano G, eds. Hemostasis, prostaglandins, and renal disease. New York, Raven, 1980:413
93. Lian EC-Y. Pathogenesis of thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:82-100
94. Lichtin AE, Schreiber AD, Hurwitz S, et al. Efficacy of intensive plasmapheresis in thrombotic thrombocytopenic purpura. Arch Intern Med 1987;147:2122-2126
95. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-397
96. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med 1991;325:398-403
97. Moake JL. TTP - desperation, empiricism, progress. N Engl J Med 1991;325:426-428
98. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32:710-714
99. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Arch Intern Med 1992;152:791-796
100. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987;24:194-201
101. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990;34:169-174
102. Obrador GT, Zeigler ZR, Shadduck RK, et al. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993;42:217-220
103. Gaddis T, Guthrie T, Mittelman A, et al. Protein A immunoadsorption (PAI) in classical thrombotic thrombocytopenia purpura (TTP) refractory to plasma exchange. Report of eleven patients. Blood 1992;80(suppl):63a
104. Kunicki TJ, Beardsley DS. The alloimmune thrombocytopenias: neonatal alloimmune thrombocytopenic purpura and post-transfusion purpura. Prog Hemost Thromb 1989; 9:203-232
105. Lau P, Sholtis CM, Aster RH. Past-transfusion purpura: an enigma of alloimmunization. Am J Hematol 1980;9:331-336
106. Lockwood CM, Boulton-Jones JM, Lowenthal RM, et al. Recovery from Good pasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975; 2:252-254
107. McCarthy LJ, Cotton J, Danielson C, et al. Goodpasture's syndrome in childhood: treatment with plasmapheresis and immunosuppression. J Clin Apheresis 1994;9:116-119
108. Jennette JC, Charles LA, Falk RJ. Antineutrophil cytoplasmic autoantibodies: disease associations, molecular biology and pathophysiology. Int Rev Exp Pathol 1991;32:193-221
109. Volpi A, Sinico RA, Conte F, Sessa A. Antineutrophil cytoplasmic antibodies associated with Goodpasture's syndrome. Contrib Nephrol 1991;94:98-100
110. Ghiringhelli P, Anghinolfi M, Marchioni M, et al. Goodpasture's syndrome with antineutrophil cytoplasm antibodies. Contrib Nephrol 1991;94:195-198
111. O'Donoghue DJ, Short CD, Brenchley PEC, et al. Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 1989;32:251-255
112. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1993;329:2019-2026
113. Johnson JP, Whitman W, Briggs WA, Wilson CB. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome. Am J Med 1978;64:354-359
114. Erickson SB, Kurtz SB, Donadio JV Jr, et al. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin Proc 1979;54: 714-720
115. Glöckner WM, Sieberth HG, Wichmann HE, et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol 1988;29:1-8